{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:13:26Z","timestamp":1780463606611,"version":"3.54.1"},"publisher-location":"Boston, MA","reference-count":149,"publisher":"Springer US","isbn-type":[{"value":"9781461378372","type":"print"},{"value":"9781461561897","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998]]},"DOI":"10.1007\/978-1-4615-6189-7_13","type":"book-chapter","created":{"date-parts":[[2011,6,9]],"date-time":"2011-06-09T04:33:40Z","timestamp":1307594020000},"page":"231-254","source":"Crossref","is-referenced-by-count":11,"title":["Endocrine therapy in metastatic breast cancer"],"prefix":"10.1007","author":[{"given":"Gretchen G.","family":"Kimmick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyman B.","family":"Muss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"13_CR1","first-page":"5","volume":"65","author":"SL Parker","year":"1996","unstructured":"Parker SL, Tong T, Bolden S, Wingo PA. 1996. Cancer Statistics, 1996. CA 65:5\u201327.","journal-title":"Cancer Statistics"},{"key":"13_CR2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/0003-4819-104-4-455","volume":"104","author":"SG Taylor","year":"1986","unstructured":"Taylor SG, Gelman RS, Falkson G, Cummings H. 1986. Combination chemotherapy corn-pared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 104:455\u2013461.","journal-title":"Ann Intern Med"},{"key":"13_CR3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.1986.4.2.186","volume":"4","author":"Anonymous","year":"1986","unstructured":"Anonymous. 1986. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. J Clin Oncol 4:186\u2013193.","journal-title":"J Clin Oncol"},{"key":"13_CR4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF01811960","volume":"21","author":"HB Muss","year":"1992","unstructured":"Muss HB. 1992. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 21:15\u201326.","journal-title":"Breast Cancer Res Treat"},{"key":"13_CR5","first-page":"877","volume":"9","author":"G Kimmick","year":"1995","unstructured":"Kimmick G, Muss HB, 1995. Current status of endocrine therapy for metastatic breast cancer. Contemp Oncol 9:877\u2013890.","journal-title":"Contemp Oncol"},{"key":"13_CR6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(01)72307-0","volume":"2","author":"GT Beatson","year":"1896","unstructured":"Beatson GT. 1896. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 2:104\u2013107.","journal-title":"Lancet"},{"key":"13_CR7","first-page":"95","volume-title":"Ovarian ablation as treatment for young women with breast cancer (review)","author":"NE Davidson","year":"1994","unstructured":"Davidson NE. 1994. Ovarian ablation as treatment for young women with breast cancer (review). Monogr Nat cancer Inst \u2022\u2022:95\u201399."},{"key":"13_CR8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1210\/edrv-11-2-221","volume":"11","author":"RJ Santen","year":"1990","unstructured":"Santen RJ, Manni A, Harvey H, Redmond C. 1990. Endocrine treatment of breast cancer in women (review). Endocrine Rev 11:221\u2013265.","journal-title":"Endocrine Rev"},{"key":"13_CR9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0277-5379(90)90628-7","volume":"26","author":"M Dowsett","year":"1990","unstructured":"Dowsett M. 1990. Novel approaches to the endocrine therapy of breast cancer (review). Eur J Cancer 26:989\u2013992.","journal-title":"Eur J Cancer"},{"key":"13_CR10","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jcem-27-9-1239","volume":"27","author":"R Cash","year":"1967","unstructured":"Cash R, Brough AJ, Cohen MN, Satoh PS. 1967. Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. J Clin Endocrinol Metab 27:1239\u20131248.","journal-title":"J Clin Endocrinol Metab"},{"key":"13_CR11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/1097-0142(197307)32:1<31::AID-CNCR2820320104>3.0.CO;2-5","volume":"32","author":"CT Griffiths","year":"1973","unstructured":"Griffiths CT, Hall TC, Saba Z, Barlow JJ, Nevinny HB. 1973. Preliminary trial of aminoglutethimide in breast cancer. Cancer 32:31\u201337.","journal-title":"Cancer"},{"key":"13_CR12","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/1097-0142(19840315)53:6<1333::AID-CNCR2820530619>3.0.CO;2-7","volume":"53","author":"T Nemoto","year":"1984","unstructured":"Nemoto T, Patel J, Rosner D, Dao TL. 1984. Tamoxifen (Nolvadex) versus adrenalectomy in metastatic breast cancer. Cancer 53:1333\u20131335.","journal-title":"Cancer"},{"key":"13_CR13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM198109033051003","volume":"305","author":"RJ Santen","year":"1981","unstructured":"Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA. 1981. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305:545\u2013551.","journal-title":"N Engl J Med"},{"key":"13_CR14","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/1097-0142(19800315)45:6<1322::AID-CNCR2820450609>3.0.CO;2-K","volume":"45","author":"DT Kiang","year":"1980","unstructured":"Kiang DT, Frenning DH, Vosika GJ, Kennedy BJ. 1980. Comparison of tamoxifen and hypophysectomy in breast cancer treatment. Cancer 45:1322\u20131325.","journal-title":"Cancer"},{"key":"13_CR15","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1002\/1097-0142(197906)43:6<2207::AID-CNCR2820430608>3.0.CO;2-1","volume":"43","author":"HA Harvey","year":"1979","unstructured":"Harvey HA, Santen RJ, Osterman J, Samojlik E, White DS, Lipton A. 1979. A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer 43:2207\u20132214.","journal-title":"Cancer"},{"key":"13_CR16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0960-0760(90)90390-7","volume":"37","author":"WR Miller","year":"1990","unstructured":"Miller WR. 1990. Endocrine treatment for breast cancers: biological rationale and current progress. J Steroid Biochem Mol Biol 37:467\u2013480.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"13_CR17","first-page":"207","volume-title":"The Basic Science of Oncology","author":"DJ Sutherland","year":"1992","unstructured":"Sutherland DJ, Mobbs BG. 1992. Hormones and cancer. In Tannock IF, Hill RP, eds. The Basic Science of Oncology, 2nd ed. New York: McGraw-Hill, Health Professions Division, pp. 207\u2013232.","edition":"2"},{"key":"13_CR18","first-page":"327","volume-title":"Diagnosis and Management of Breast Cancer","author":"ME Lippman","year":"1988","unstructured":"Lippman ME. 1988. Steroid hormone receptors and mechanisms of growth regulation of human breast cancer. In Lippman ME, Lichtner AS, Danforth DN, eds. Diagnosis and Management of Breast Cancer. Philadelphia: W.B. Saunders, pp. 327\u2013347."},{"key":"13_CR19","first-page":"135","volume":"172","author":"Editorial","year":"1960","unstructured":"Editorial. 1960. Androgens and estrogens in the treatment of disseminated mammary carcinoma. Retrospective study of nine hundred forty-four patients. Report of the Council on Drugs. JAMA 172:135\u2013147.","journal-title":"JAMA"},{"key":"13_CR20","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1001\/jama.1977.03270460065023","volume":"237","author":"AC Carter","year":"1977","unstructured":"Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR. 1977. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 237:2079\u20132080.","journal-title":"JAMA"},{"key":"13_CR21","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0889-8588(18)30531-8","volume":"3","author":"KI Pritchard","year":"1989","unstructured":"Pritchard KI, Sutherland DJA. 1989. Diagnosis and therapy of breast cancer: the use of endocrine therapy. Hematol Oncol Clin North Am 3:765\u2013805.","journal-title":"Hematol Oncol Clin North Am"},{"key":"13_CR22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/1097-0142(19810815)48:4<883::AID-CNCR2820480404>3.0.CO;2-V","volume":"48","author":"MJ Minton","year":"1981","unstructured":"Minton MJ, Knight RK, Rubens RD, Hayward JL. 1981. Corticosteroids for elderly patients with breast cancer. Cancer 48:883\u2013887.","journal-title":"Cancer"},{"key":"13_CR23","first-page":"751","volume":"69","author":"E Bruera","year":"1985","unstructured":"Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. 1985. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69:751\u2013754.","journal-title":"Cancer Treat Rep"},{"key":"13_CR24","first-page":"4595","volume":"36","author":"M Lippman","year":"1976","unstructured":"Lippman M, Bolan G, Huff K. 1976. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36:4595\u20134601.","journal-title":"Cancer Res"},{"key":"13_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00662395","volume":"25","author":"AE Wakeling","year":"1993","unstructured":"Wakeling AE. 1993. The future of new pure antiestrogens in clinical breast cancer (review). Breast Cancer Res Treat 25:1\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"13_CR26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0305-7372(88)90002-3","volume":"15","author":"S Litherland","year":"1988","unstructured":"Litherland S, Jackson IM. 1988. Antioestrogens in the management of hormone-dependent cancer. Cancer Treat Rev 15:183\u2013194.","journal-title":"Cancer Treat Rev"},{"key":"13_CR27","first-page":"290","volume":"109","author":"A Manni","year":"1987","unstructured":"Manni A. 1987. Tamoxifen therapy of metastatic breast cancer. J Lab Clin Med 109:290\u2013299.","journal-title":"J Lab Clin Med"},{"key":"13_CR28","first-page":"559","volume-title":"Breast Diseases","author":"IC Henderson","year":"1991","unstructured":"Henderson IC. 1991. Endocrine therapy of metastatic breast cancer. In Harris JR, Hellman S, Henderson IC, Kinne DW, eds. Breast Diseases, 2nd ed. New York: Lippincott, pp. 559\u2013603.","edition":"2"},{"key":"13_CR29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(87)90717-3","volume":"1","author":"PA Canney","year":"1987","unstructured":"Canney PA, Griffiths T, Latief TN, Priestman TJ. 1987. Clinical significance of tamoxifen withdrawal response (letter). Lancet 1:36.","journal-title":"Lancet"},{"key":"13_CR30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/00003495-198937040-00004","volume":"37","author":"MM Buckley","year":"1989","unstructured":"Buckley MM, Goa KL. 1989. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use (review). Drugs 37:451\u2013490.","journal-title":"Drugs"},{"key":"13_CR31","first-page":"7193","volume":"48","author":"C Malet","year":"1988","unstructured":"Malet C, Gompel A, Spritzer P, Bricout N, Yaneva H, Mowszowicz I, Mauvais-Jarvis P. 1988. Tamoxifen and hydroxytamoxifen isomers versus estradiol effects on normal human breast cells in culture. Cancer Res 48:7193\u20137199.","journal-title":"Cancer Res"},{"key":"13_CR32","first-page":"349","volume":"54","author":"PS Karnik","year":"1994","unstructured":"Karnik PS, Kulkarni S, Liu XP, Budd GT, Bukowski RM. 1994. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 54:349\u2013353.","journal-title":"Cancer Res"},{"key":"13_CR33","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/jnci\/83.20.1434","volume":"83","author":"BS Katzenellenbogen","year":"1991","unstructured":"Katzenellenbogen BS. 1991. Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy (editorial; comment). J Natl Cancer Inst 83:1434\u20131435.","journal-title":"J Natl Cancer Inst"},{"key":"13_CR34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00666162","volume":"31","author":"S Paik","year":"1994","unstructured":"Paik S, Hartmann DP, Dickson RB, Lippman ME. 1994. Antiestrogen resistance in ER positive breast cancer cells (review). Breast Cancer Res Treat 31:301\u2013307.","journal-title":"Breast Cancer Res Treat"},{"key":"13_CR35","first-page":"1521","volume":"46","author":"P Mauvais-Javis","year":"1986","unstructured":"Mauvais-Javis P, Baudot N, Castaigne D, Banzet P, Kuttenn F. 1986. Trans-4Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast. Cancer Res 46:1521\u20131525.","journal-title":"Cancer Res"},{"key":"13_CR36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0022-4731(87)90387-6","volume":"28","author":"C Murphy","year":"1987","unstructured":"Murphy C, Fotsis T, Pantzar P, Adlercreutz H, Martin F. 1987. Analysis of tamoxifen, Ndesmethyltamoxifen and 4-hydroxytamoxifen levels in cytosol and KC1-nuclear extracts of breast tumours from tamoxifen treated patients by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). J Steroid Biochem 28:609\u2013618.","journal-title":"J Steroid Biochem"},{"key":"13_CR37","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1992.10.2.304","volume":"10","author":"CK Osborne","year":"1992","unstructured":"Osborne CK, Wiebe VJ. McGuire WL, Ciocca DR, DeGregorio MW. 1992. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 10:304\u2013310.","journal-title":"J Clin Oncol"},{"key":"13_CR38","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1200\/JCO.1992.10.6.990","volume":"10","author":"VJ Wiebe","year":"1992","unstructured":"Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW. 1992. Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 10:990\u2013994.","journal-title":"J Clin Oncol"},{"key":"13_CR39","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/jnci\/85.10.806","volume":"85","author":"DM Wolf","year":"1993","unstructured":"Wolf DM, Langan-Fahey SM, Parker CJ, McCague R, Jordan VC. 1993. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl cancer Inst 85:806\u2013812.","journal-title":"J Natl cancer Inst"},{"key":"13_CR40","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0277-5379(85)90077-X","volume":"21","author":"A Clarysse","year":"1985","unstructured":"Clarysse A. 1985. Hormone-induced tumor flare (editorial). Eur J Cancer Clin Oncol 21:545\u2013547.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"13_CR41","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1001\/jama.1978.03290240044022","volume":"240","author":"D Plotkin","year":"1978","unstructured":"Plotkin D, Lechner JJ, Jung WE, Rosen PJ. 1978. Tamoxifen flare in advanced breast cancer. JAMA 240:2644\u20132646.","journal-title":"JAMA"},{"key":"13_CR42","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0014-2964(81)90311-X","volume":"17","author":"DP Rose","year":"1981","unstructured":"Rose DP, Fischer AH, Jordan VC, 1981. Activity of the antioestrogen trioxifene against NNitrosomethylurea-induced rat mammry carcinomas. Eur J Cancer Clin Oncol 17:893\u2013898.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"13_CR43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/1097-0142(19860101)57:1<34::AID-CNCR2820570109>3.0.CO;2-W","volume":"57","author":"RS Witte","year":"1986","unstructured":"Witte RS, Pruitt B, Tormey DC, Moss S, Rose DP, Falkson G, Carbone PP, Ramirez G, Falkson H, Pretorius FJ. 1986. A phase I\/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologie effects. Cancer 57:34\u201339.","journal-title":"Cancer"},{"key":"13_CR44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/1097-0142(19860101)57:1<40::AID-CNCR2820570110>3.0.CO;2-W","volume":"57","author":"RW Lee","year":"1986","unstructured":"Lee RW, Buzdar AU, Blumenschein GR, Hortobagyi GN. 1986. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer 57:40\u201343.","journal-title":"Cancer"},{"key":"13_CR45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0022-4731(90)90019-O","volume":"36","author":"M Anttila","year":"1990","unstructured":"Anttila M, Valavaara R, Kivinen S, Maenpaa J. 1990. Pharmacokinetics of toremifene. J Steroid Biochem 36:249\u2013252.","journal-title":"J Steroid Biochem"},{"key":"13_CR46","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/BF01807138","volume":"16","author":"L Kangas","year":"1990","unstructured":"Kangas L. 1990. Introduction to toremifene (review). Breast Cancer Res Treat 16 (Suppl):S3\u2013S7.","journal-title":"Breast Cancer Res Treat"},{"key":"13_CR47","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1007\/BF01807142","volume":"16","author":"R Valavaara","year":"1990","unstructured":"Valavaara R. 1990. Phase II trials with toremifene in advanced breast cancer: a review. Breast Cancer Res Treat 16 (Suppl):S31\u2013S35.","journal-title":"Breast Cancer Res Treat"},{"key":"13_CR48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00662401","volume":"25","author":"LE Stenbygaard","year":"1993","unstructured":"Stenbygaard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SA. 1993. Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial. Breast Cancer Res Treat 25:57\u201363.","journal-title":"Breast Cancer Res Treat"},{"key":"13_CR49","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.1993.11.2.345","volume":"11","author":"CL Vogel","year":"1993","unstructured":"Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR. 1993. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol 11:345\u2013350.","journal-title":"J Clin Oncol"},{"key":"13_CR50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1254\/jjp.63.27","volume":"63","author":"I Kawamura","year":"1993","unstructured":"Kawamura I, Mizota T, Lacey E, Tanaka Y, Manda T, Shimomura K, Kohsaka M. 1993. The estrogenic and antiestrogenic activities of droloxifene in human breast cancers. Jpn J Pharmacol 63:27\u201334.","journal-title":"Jpn J Pharmacol"},{"key":"13_CR51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF00685906","volume":"33","author":"AU Buzdar","year":"1994","unstructured":"Buzdar AU, Kau S, Hortobagyi GN, Theriault RL, Booser D, Holmes FA, Walters R, Krakoff IH. 1994. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol 33:313\u2013316.","journal-title":"Cancer Chemother Pharmacol"},{"key":"13_CR52","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/0959-8049(92)90530-F","volume":"28A","author":"PF Bruning","year":"1992","unstructured":"Bruning PF. 1992. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer 28A:1404\u20131407.","journal-title":"Eur J Cancer"},{"issue":"2","key":"13_CR53","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1097\/00000421-199112002-00011","volume":"14","author":"L Deschenes","year":"1991","unstructured":"Deschenes L. 1991. Droloxifene, a new antiestrogen, in advanced breast cancer. A double-blind dose-finding study. The Droloxifene 002 International Study Group. Am J Clin Oncol 14 (Suppl 2):S52\u2013S55.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"13_CR54","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1097\/00000421-199112002-00008","volume":"14","author":"J Bellmunt","year":"1991","unstructured":"Bellmunt J, Sole L. 1991. European early phase II dose-finding study of droloxifene in advanced breast cancer. Am J Clin Oncol 14 (Suppl 2):S36\u2013S39.","journal-title":"Am J Clin Oncol"},{"key":"13_CR55","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3109\/02841869209088284","volume":"31","author":"H Haarstad","year":"1992","unstructured":"Haarstad H, Gundersen S, Wist E, Raabe N, Mella O, Kvinnsland S. 1992. Droloxifene - a new anti-estrogen. A phase II study in advanced breast cancer. Acta Oncol 31:425\u2013428.","journal-title":"Acta Oncol"},{"key":"13_CR56","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.1990.99","volume":"61","author":"RC Stein","year":"1990","unstructured":"Stein RC, Dowsett M, Cunningham DC, Davenport J, Ford HT, Gazet JC, Coombes RC. 1990. Phase I\/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I\/II Clinical Trials Committee study. Br J Cancer 61:451\u2013453.","journal-title":"Br J Cancer"},{"key":"13_CR57","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-3-642-84745-5_35","volume":"127","author":"RC Coombes","year":"1993","unstructured":"Coombes RC, Jarman M, Dowsett M. 1993. New endocrine agents for the treatment of breast cancer. Recent Results in Cancer Res 127:267.","journal-title":"Recent Results in Cancer Res"},{"key":"13_CR58","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0960-0760(90)90418-K","volume":"37","author":"AE Wakeling","year":"1990","unstructured":"Wakeling AE. 1990. Therapeutic potential of pure antioestrogens in the treatment of breast cancer (review). J Steroid Biochem Mol Biol 37:771\u2013775.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"13_CR59","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1749-6632.1990.tb34308.x","volume":"595","author":"AE Wakeling","year":"1990","unstructured":"Wakeling AE. 1990. Novel pure antiestrogens. Mode of action and therapeutic prospects. Ann NY Acad Sci 595:348\u2013356.","journal-title":"Ann NY Acad Sci"},{"key":"13_CR60","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01805977","volume":"14","author":"R Poulin","year":"1989","unstructured":"Poulin R, Merand Y, Poirier D, Levesque C, Dufour JM, Labrie F. 1989. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164,384, a new steroidal antiestrogen, in ZR-75\u20131 human breast cancer cells. Breast Cancer Res Treat 14:65\u201376.","journal-title":"Breast Cancer Res Treat"},{"key":"13_CR61","first-page":"6929","volume":"49","author":"EW Thompson","year":"1989","unstructured":"Thompson EW, Katz D, Shima TB, Wakeling AE, Lippman ME, Dickson RB. 1989. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res 49:6929\u20136934.","journal-title":"Cancer Res"},{"key":"13_CR62","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-1-4684-5101-6_22","volume":"196","author":"DA Bronzert","year":"1986","unstructured":"Bronzert DA, Davidson N, Lippman M. 1986. Estrogen and antiestrogen resistance in human breast cancer cell lines (review). Adv Exp Med Biol 196:329\u2013345.","journal-title":"Adv Exp Med Biol"},{"key":"13_CR63","first-page":"4090","volume":"49","author":"MM Gottardis","year":"1989","unstructured":"Gottardis MM, Jiang SY, Jeng MH, Jordan VC. 1989. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090\u20134093.","journal-title":"Cancer Res"},{"key":"13_CR64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0960-0760(92)90204-V","volume":"43","author":"AE Wakeling","year":"1992","unstructured":"Wakeling AE, Bowler J. 1992. ICI 182,780, a new antioestrogen with clinical potential (review). J Steroid Biochem Mol Biol 43:173\u2013177.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"13_CR65","first-page":"3867","volume":"51","author":"AE Wakeling","year":"1991","unstructured":"Wakeling AE, Dukes M, Bowler J. 1991. A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867\u20133873.","journal-title":"Cancer Res"},{"key":"13_CR66","first-page":"408","volume":"54","author":"DJ Friend De","year":"1994","unstructured":"DeFriend DJ, Howell A, Nicholson RI, et al. 1994. Investigation of a new pure antiestrogen (ICI 182,780) in women with primary breast cancer. Cancer Res 54:408\u2013414.","journal-title":"Cancer Res"},{"key":"13_CR67","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(95)91156-1","volume":"345","author":"A Howell","year":"1995","unstructured":"Howell A, DeFriend D, Robertson J, Blarney R, Walton P. 1995. Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer (see comments). Lancet 345:29\u201330.","journal-title":"Lancet"},{"key":"13_CR68","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0960-0760(90)90421-G","volume":"37","author":"GH Bakker","year":"1990","unstructured":"Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JG. 1990. Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 37:789\u2013794.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"13_CR69","first-page":"683","volume":"10","author":"MR Schneider","year":"1990","unstructured":"Schneider MR, Michna H, Nishino Y, Neef G, el Etreby MF. 1990. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors. Anticancer Res 10:683\u2013687.","journal-title":"Anticancer Res"},{"key":"13_CR70","first-page":"1091","volume":"71","author":"D Cunningham","year":"1987","unstructured":"Cunningham D, Gazet J, Ford HT, Coombes RC. 1987. Oral gestrinone: a novel antiprogestin with no antitumor activity in endocrine-sensitive breast cancer. Cancer Treat Rep 71:1091\u20131092.","journal-title":"Cancer Treat Rep"},{"key":"13_CR71","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00175399","volume":"6","author":"DJ Perrault","year":"1988","unstructured":"Perrault DJ, Logan DM, Stewart DJ, Bramwell VH, Paterson AH, Eisenhauer EA. 1988. Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs 6:207\u2013210.","journal-title":"Invest New Drugs"},{"key":"13_CR72","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-1-4613-1731-9_5","volume":"39","author":"A Manni","year":"1988","unstructured":"Manni A, Santen RJ. 1988. Clinical use of aromatase inhibitors in the treatment of breast cancer (review). Cancer Treat Res 39:67\u201381.","journal-title":"Cancer Treat Res"},{"key":"13_CR73","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-96-1-94","volume":"96","author":"RJ Santen","year":"1982","unstructured":"Santen RJ, Worgul TJ, Lipton A, Harvey H, Boucher A, Samojlik E, Wells SA. 1982. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med 96:94\u2013101.","journal-title":"Ann Intern Med"},{"key":"13_CR74","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0305-7372(84)90008-2","volume":"11","author":"RC Stuart-Harris","year":"1984","unstructured":"Stuart-Harris RC, Smith IE. 1984. Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 11:189\u2013204.","journal-title":"Cancer Treat Rev"},{"key":"13_CR75","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.1994.12.11.2460","volume":"12","author":"PE Goss","year":"1994","unstructured":"Goss PE, Gwyn KM. 1994. Current perspectives on aromatase inhibitors in breast cancer (review). J Clin Oncol 12:2460\u20132470.","journal-title":"J Clin Oncol"},{"key":"13_CR76","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.1992.10.3.438","volume":"10","author":"P Bolufer","year":"1992","unstructured":"Bolufer P, Ricart E, Lluch A, Vazquez C, Rodriguez A, Ruiz A, Llopis F, Garcia-Conde J, Romero R. 1992. Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging. J Clin Oncol 10:438\u2013446.","journal-title":"J Clin Oncol"},{"key":"13_CR77","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/1097-0142(19800215)45:4<786::AID-CNCR2820450429>3.0.CO;2-X","volume":"45","author":"BV Lawrence","year":"1980","unstructured":"Lawrence BV, Lipton A, Harvey HA, Santen RJ, Wells SA Jr, Cox CE, Smart EK. 1980. Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. Cancer 45:786\u2013791.","journal-title":"Cancer"},{"key":"13_CR78","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/0277-5379(86)90147-1","volume":"22","author":"HE Wander","year":"1986","unstructured":"Wander HE, Blossey HC, Nagel GA. 1986. Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. Eur J Cancer Clin Oncol 22:1371\u20131374.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"13_CR79","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3109\/02841869009092989","volume":"29","author":"G Brufman","year":"1990","unstructured":"Brufman G, Biran S. 1990. Second line hormonal therapy with aminoglutethimide in metastatic breast cancer. Acta Oncol 29:717\u2013720.","journal-title":"Acta Oncol"},{"key":"13_CR80","first-page":"1003","volume":"69","author":"AA Messeih","year":"1985","unstructured":"Messeih AA, Lipton A, Santen RJ, Harvey HA, Boucher AE, Murray R, Ragaz J, Buzdar AU, Nagel GA, Henderson IC. 1985. Aminoglutethimide-induced hematologic toxicity: worldwide experience. Cancer Treat Rep 69:1003\u20131004.","journal-title":"Cancer Treat Rep"},{"key":"13_CR81","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1021\/jm00380a009","volume":"28","author":"AB Foster","year":"1985","unstructured":"Foster AB, Jarman M, Leung CS, Rowlands MG, Taylor GN, Plevey RG. 1985. Analogues of aminoglutethimide: selective inhibition of aromatase. J Med Chem 28:200\u2013204.","journal-title":"J Med Chem"},{"key":"13_CR82","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00688859","volume":"27","author":"BP Haynes","year":"1991","unstructured":"Haynes BP, Jarman M, Dowsett M, Mehta A, Lonning PE, Griggs LJ, Powles T, Stein R, Coombes RC. 1991. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemother Pharmacol 27:367\u2013372.","journal-title":"Cancer Chemother Pharmacol"},{"key":"13_CR83","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0960-0760(95)00045-2","volume":"53","author":"PV Plourde","year":"1995","unstructured":"Plourde PV, Dyroff M, Dowsett M, Demers L, Yates R, Webster A. 1995. ARIMIDEX: a new oral, once-a-day aromatase inhibitor (review). J Steroid Biochem Mol Biol 53:175\u2013179.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"13_CR84","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0959-8049(95)00014-3","volume":"32A","author":"W Jonat","year":"1996","unstructured":"Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M. 1996. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Armidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A:404\u2013412.","journal-title":"Eur J Cancer"},{"key":"13_CR85","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0960-0760(91)90029-5","volume":"39","author":"M Dowsett","year":"1991","unstructured":"Dowsett M. 1991. Inhibitors of steroidogenic enzymes for the treatment of breast cancer (review). J Steroid Biochem Mol Biol 39:805\u2013809.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"13_CR86","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/bjc.1993.506","volume":"68","author":"CJ Williams","year":"1993","unstructured":"Williams CJ, Barley VL, Blackledge GR, Rowland CG, Tyrrell CJ. 1993. Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. Br J Cancer 68:1210\u20131215.","journal-title":"Br J Cancer"},{"key":"13_CR87","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0022-4731(86)90037-3","volume":"24","author":"AM Brodie","year":"1986","unstructured":"Brodie AM, Wing LY, Goss P, Dowsett M, Coombes RC. 1986. Aromatase inhibitors and the treatment of breast cancer. J Steroid Biochem 24:91\u201397.","journal-title":"J Steroid Biochem"},{"key":"13_CR88","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/bjc.1990.284","volume":"62","author":"T Pickles","year":"1990","unstructured":"Pickles T, Perry L, Murray P, Plowman P. 1990. 4-hydroxyandrostenedione - further clinical and extended endocrine observations. Br J Cancer 62:309\u2013313.","journal-title":"Br J Cancer"},{"key":"13_CR89","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF02940300","volume":"26","author":"RC Stein","year":"1990","unstructured":"Stein RC, Dowsett M, Hedley A, Davenport J, Gazet JC, Ford HT. 1990. Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione. Cancer Chemother Pharmacol 26:75\u201378.","journal-title":"Cancer Chemother Pharmacol"},{"key":"13_CR90","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1200\/JCO.1990.8.5.875","volume":"8","author":"K Hoffken","year":"1990","unstructured":"Hoffken K, Jonat W, Possinger K, et al. 1990. Aromatase inhibition with 4hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. J Clin Oncol 8:875\u2013880.","journal-title":"J Clin Oncol"},{"issue":"7","key":"13_CR91","first-page":"S7","volume":"5","author":"K Possinger","year":"1994","unstructured":"Possinger K, Jonat W, Hoffken K. 1994. Formestane in the treatment of advanced postmenopausal breast cancer. Ann Oncol 5 (Suppl 7):S7\u2013S10.","journal-title":"Ann Oncol"},{"key":"13_CR92","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/BF01225692","volume":"121","author":"N Zilembo","year":"1995","unstructured":"Zilembo N, Bajetta E, Noberasco C, Buzzoni R, Vicario G, Bono A, Laffranchi A, Biasi G, Dolci S, Bichisao E. 1995. Formestane: an effective first-line endocrine treatment for advanced breast cancer. J Cancer Res Clin Oncol 121:378\u2013382.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"13_CR93","first-page":"S19","volume":"5","author":"R Perez Carrion","year":"1994","unstructured":"Perez Carrion R, Alberola Candel V, Calabresi F, et al. 1994. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 5 (Suppl 7):S19\u2013S24.","journal-title":"Ann Oncol"},{"key":"13_CR94","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0039-128X(83)90075-2","volume":"50","author":"RC Coombes","year":"1987","unstructured":"Coombes RC, Goss PE, Dowsett M, Hutchinson G, Cunningham D, Jarman M. 1987. 4Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Steroids 50:245\u2013252.","journal-title":"Steroids"},{"key":"13_CR95","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/bjc.1995.451","volume":"72","author":"N Zilembo","year":"1995","unstructured":"Zilembo N, Noberasco C, Bajetta E, et al. 1995. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 72:1007\u20131012.","journal-title":"Br J Cancer"},{"key":"13_CR96","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/1097-0142(19900315)65:6<1279::AID-CNCR2820650604>3.0.CO;2-3","volume":"65","author":"A Lipton","year":"1990","unstructured":"Lipton A, Harvey HA, Demers LM, Hanagan JR, Mulagha MT, Kochak GM, Sanders SI, Santen RJ. 1990. A phase I trial of CGS 16949A. A new aromatase inhibitor. Cancer 65:1279\u20131285.","journal-title":"Cancer"},{"key":"13_CR97","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/0960-0760(93)90282-2","volume":"44","author":"LM Demers","year":"1993","unstructured":"Demers LM, Lipton A, Harvey HA, Hanagan J, Mulagha M, Santen RJ. 1993. The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer. J Steroid Biochem Mol Biol 44:683\u2013685.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"13_CR98","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1210\/jcem-73-1-99","volume":"73","author":"RJ Santen","year":"1991","unstructured":"Santen RJ, Demers LM, Lynch J, et al. 1991. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J Clin Endocrinol Metab 73:99\u2013106.","journal-title":"J Clin Endocrinol Metab"},{"key":"13_CR99","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1200\/JCO.1992.10.1.111","volume":"10","author":"JI Raats","year":"1992","unstructured":"Raats JI, Falkson G, Falkson HC. 1992. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J Clin Oncol 10:111\u2013116.","journal-title":"J Clin Oncol"},{"key":"13_CR100","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/0960-0760(90)90460-3","volume":"37","author":"AS Bhatnagar","year":"1990","unstructured":"Bhatnagar AS, Hausler A, Schieweck K, Lang M, Bowman R. 1990. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor (review). J Steroid Biochem Mol Biol 37:1021\u20131027.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"13_CR101","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/030006059202000401","volume":"20","author":"N Perez","year":"1992","unstructured":"Perez N, Borja J. 1992. Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer. J Int Med Res 20:303\u2013312.","journal-title":"J Int Med Res"},{"key":"13_CR102","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/1097-0142(19950415)75:8<2132::AID-CNCR2820750816>3.0.CO;2-U","volume":"75","author":"A Lipton","year":"1995","unstructured":"Lipton A, Demers LM, Harvey HA, Kambic KB, Grossberg H, Brady C, Adlercruetz H, Trunet PF, Santen RJ. 1995. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 75:2132\u20132138.","journal-title":"Cancer"},{"key":"13_CR103","first-page":"266","volume":"53","author":"TJ Iveson","year":"1993","unstructured":"Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M. 1993. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 53:266\u2013270.","journal-title":"Cancer Res"},{"key":"13_CR104","first-page":"71","volume":"13","author":"M Dowsett","year":"1994","unstructured":"Dowsett M, Johnston SRD, Doody D, et al. 1994. The clinical and endocrine effects of the oral aromatase inhibitor vorozole in human breast cancer (abstract). Proc ASCO 13:71.","journal-title":"Proc ASCO"},{"key":"13_CR105","first-page":"88","volume":"13","author":"PE Goss","year":"1994","unstructured":"Goss PE, Clark R, Ambus U, et al. 1994. Phase II study of vorozole (R 83842) a new aromatase inhibitor in postmenopausal women with advanced breast cancer (abstract). Proc ASCO 13:88.","journal-title":"Proc ASCO"},{"key":"13_CR106","first-page":"105","volume":"13","author":"J Vinholes","year":"1994","unstructured":"Vinholes J, Paridains R, Piccart MJ, et al. 1994. An EORTC breast group phase II study of vorozole (R 83842), a new aromatase inhibitor in advanced breast cancer (abstract). Proc ASCO 13:105.","journal-title":"Proc ASCO"},{"key":"13_CR107","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jama.1973.03220110045012","volume":"223","author":"IS Goldenberg","year":"1973","unstructured":"Goldenberg IS, Waters N, Ravdin RS, Ansfield FJ, Segaloff A. 1973. Androgenic therapy for advanced breast cancer in women. A report of the Cooperative Breast Cancer Group. JAMA 223:1267\u20131268.","journal-title":"JAMA"},{"key":"13_CR108","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1002\/1097-0142(19811201)48:11<2507::AID-CNCR2820481127>3.0.CO;2-E","volume":"48","author":"A Manni","year":"1981","unstructured":"Manni A, Arafah BM, Pearson Oh. 1981. Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer. Cancer 48:2507\u20132509.","journal-title":"Cancer"},{"key":"13_CR109","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/1097-0142(197712)40:6<2797::AID-CNCR2820400607>3.0.CO;2-9","volume":"40","author":"TG Peters","year":"1977","unstructured":"Peters TG, Lewis JD, Wilkinson EJ, Fuhrman TM. 1977. Danazol therapy in hormone-sensitive mammary carcinoma. Cancer 40:2797\u20132800.","journal-title":"Cancer"},{"key":"13_CR110","first-page":"1073","volume":"64","author":"RC Coombes","year":"1980","unstructured":"Coombes RC, Dearnaley D, Humphreys J, Gazet JC, Ford HT, Nash AG, Mashiter K, Powles TJ. 1980. Danazol treatment of advanced breast cancer. Cancer Treat Rep 64:1073\u20131076.","journal-title":"Cancer Treat Rep"},{"key":"13_CR111","first-page":"194","volume":"10","author":"RC Coombes","year":"1983","unstructured":"Coombes RC, Perez D, Gazet JC, Ford HT, Powles TJ. 1983. Danazol treatment for advanced breast cancer. Cancer Chemother Pharmacol 10:194\u2013195.","journal-title":"Cancer Chemother Pharmacol"},{"key":"13_CR112","first-page":"875","volume":"71","author":"HS Brodovsky","year":"1987","unstructured":"Brodovsky HS, Holroyde CP, Laucius JF, Dugery C, Serbin J. 1987. Danazol in the treatment of women with metastatic breast cancer. Cancer Treat Rep 71:875\u2013876.","journal-title":"Cancer Treat Rep"},{"key":"13_CR113","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00000421-198710000-00008","volume":"10","author":"P Pronzato","year":"1987","unstructured":"Pronzato P, Amoroso D, Ardizzoni A, Bertelli G, Conte PF, Michelotti A, Rosso R. 1987. A phase II study of danazol in metastatic breast cancer. Am J Clin Oncol 10:407\u2013409.","journal-title":"Am J Clin Oncol"},{"key":"13_CR114","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1126\/science.137.3526.257","volume":"137","author":"C Huggins","year":"1962","unstructured":"Huggins C, Yang NC. 1962. Induction and extinction of mammary cancer. Science 137:257\u2013262.","journal-title":"Science"},{"key":"13_CR115","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/BF01717830","volume":"65","author":"E Petru","year":"1987","unstructured":"Petru E, Schmahl D. 1987. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide. in advanced breast cancer. Klin Wochen 65:959\u2013966.","journal-title":"Klin Wochen"},{"key":"13_CR116","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/00016348109157810","volume":"101","author":"J Liber","year":"1981","unstructured":"Liber J, Rose C, Salimtschik M, Mouridsen HT. 1981. Treatment of advanced breast cancer with progestins. Acta Obstet Gynecol Scand - Suppl 101:39\u201346.","journal-title":"Acta Obstet Gynecol Scand - Suppl"},{"key":"13_CR117","first-page":"2","volume":"13","author":"DG Haller","year":"1986","unstructured":"Haller DG, Glick JH. 1986. Progestational agents in advanced breast cancer: an overview. Semin Oncol 13:2\u20138.","journal-title":"Semin Oncol"},{"key":"13_CR118","unstructured":"Pannuti F, Martoni A, Piana E, et al. Progestins in breast cancer. In Pannuti F, ed. Hormonotherapy: Results and Perspectives. Pavia (Italy): Edizioni, pp. 207\u2013222."},{"key":"13_CR119","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000227233","volume":"50","author":"F Parazzini","year":"1993","unstructured":"Parazzini F, Colli E, Scatigna M, Tozzi L. 1993. Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: a quantitative review of published randomized clinical trials (review). Oncology 50:483\u2013489.","journal-title":"Oncology"},{"key":"13_CR120","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0039-128X(84)80029-X","volume":"44","author":"SM Sedlacek","year":"1991","unstructured":"Sedlacek SM, Horwitz KB. 1991. The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids 44:467\u2013483.","journal-title":"Steroids"},{"key":"13_CR121","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/0014-2964(79)90097-5","volume":"15","author":"F Pannuti","year":"1979","unstructured":"Pannuti F, Martoni A, Di Marco AR, et al. 1979. Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. Eur J Cancer 15:593\u2013601.","journal-title":"Eur J Cancer"},{"key":"13_CR122","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/030089167806400204","volume":"64","author":"CGR Della","year":"1978","unstructured":"Della Cuna GR, Calciati A, Strada MRB, Bumma C, Campio L. 1978. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation. Tumori 64:143\u2013149.","journal-title":"Tumori"},{"key":"13_CR123","first-page":"77","volume-title":"Role of Medroxyprogesterone in Endocrine Related Tumors","author":"FH Cortes","year":"1983","unstructured":"Cortes Funes H, Madrigal PL, Perez Mangas G, et al. 1983. Medroxyprogesterone acetate at two different doses for the treatment of advanced breast cancer. In Campio L, Robustelli Della Cuna G, Taylor RW, eds. Role of Medroxyprogesterone in Endocrine Related Tumors, 2nd ed. New York: Raven Press, pp. 77\u201383.","edition":"2"},{"key":"13_CR124","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.1984.2.5.414","volume":"2","author":"F Cavalli","year":"1984","unstructured":"Cavalli F, Goldhirsch A, Jungi F, Martz G, Mermillod B, Alberto P. 1984. Randomized trial of low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2:414\u2013419.","journal-title":"JClin Oncol"},{"key":"13_CR125","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/0277-5379(87)90056-3","volume":"23","author":"CJ Gallagher","year":"1987","unstructured":"Gallagher CJ, Cairnduff F, Smith IE. 1987. High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer. Eur J Cancer Clin Oncol 23:1895\u20131900.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"13_CR126","first-page":"3","volume":"15","author":"SM Sedlacek","year":"1988","unstructured":"Sedlacek SM. 1988. An overview of megestrol acetate for the treatment of advanced breast cancer. Semin Oncol 15:3\u201313.","journal-title":"Semin Oncol"},{"key":"13_CR127","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000227345","volume":"51","author":"G Brufman","year":"1994","unstructured":"Brufman G, Isacson R, Haim N, Gez E, Sulkes A. 1994. Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and\/or aminoglutethimide. Oncology 51:258\u2013261.","journal-title":"Oncology"},{"key":"13_CR128","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.1990.8.11.1797","volume":"8","author":"HB Muss","year":"1990","unstructured":"Muss HB, Case LD, Capizzi RL, et al. 1990. High-versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. J Clin Oncol 8:1797\u20131805.","journal-title":"J Clin Oncol"},{"key":"13_CR129","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1994.12.8.1630","volume":"12","author":"HB Muss","year":"1994","unstructured":"Muss HB, Case LD, Atkins JN, et al. 1994. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study (see comments). J Clin Oncol 12:1630\u20131638.","journal-title":"J Clin Oncol"},{"key":"13_CR130","first-page":"3830","volume":"36","author":"ER Sombre De","year":"1976","unstructured":"DeSombre ER, Johnson ES, White WF. 1976. Regression of rat mammary tumors effected by a gonadoliberin analog. Cancer Res 36:3830\u20133833.","journal-title":"Cancer Res"},{"key":"13_CR131","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-88-470-2186-0_8","volume":"124","author":"JG Klijn","year":"1992","unstructured":"Klijn JG. 1992. LH-RH agonists in the treatment of metastatic breast cancer: ten years\u2019 experience (review). Recent Results Cancer Res 124:75\u201390.","journal-title":"Recent Results Cancer Res"},{"key":"13_CR132","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1126\/science.100883","volume":"202","author":"PE Belchetz","year":"1978","unstructured":"Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. 1978. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 202:631\u2013633.","journal-title":"Science"},{"key":"13_CR133","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1056\/NEJM199101103240205","volume":"324","author":"PM Conn","year":"1991","unstructured":"Conn PM, Crowley WF Jr. 1991. Gonadotropin-releasing hormone and its analogues (see comments) (review). N Engl J Med 324:93\u2013103.","journal-title":"N Engl J Med"},{"key":"13_CR134","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/bjc.1989.19","volume":"59","author":"AL Harris","year":"1989","unstructured":"Harris AL, Carmichael J, Cantwell BM, Dowsett M. 1989. Zolodex: endocrine and therapeutic effects in post-menopausal breast cancer. Br J Cancer 59:97\u201399.","journal-title":"Br J Cancer"},{"key":"13_CR135","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1126\/science.2992093","volume":"229","author":"KA Eidne","year":"1985","unstructured":"Eidne KA, Flanagan CA, Millar RP. 1985. Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 229:989\u2013991.","journal-title":"Science"},{"key":"13_CR136","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/313231a0","volume":"313","author":"WR Miller","year":"1985","unstructured":"Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM. 1985. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313:231\u2013233.","journal-title":"Nature"},{"key":"13_CR137","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000227346","volume":"51","author":"E Bajetta","year":"1994","unstructured":"Bajetta E, Zilembo N, Buzzoni R, Celio L, Zampino MG, Colleoni M, Oriana S, Attili A, Sacchini V, Martinetti A. 1994. Goserelin in premenopausal advanced breast cancer: clinical and endocrine evaluation of responsive patients. Oncology 51:262\u2013269.","journal-title":"Oncology"},{"key":"13_CR138","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1200\/JCO.1989.7.8.1113","volume":"7","author":"M Kaufmann","year":"1989","unstructured":"Kaufmann M, Jonat W, Kleeberg U, et al. 1989. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. J Clin Oncol 7:1113\u20131119.","journal-title":"J Clin Oncol"},{"key":"13_CR139","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/0277-5379(90)90162-M","volume":"26","author":"JR Hardy","year":"1990","unstructured":"Hardy JR, Powles TJ, Judson IR, Sinnett HD, Ashley SE, Coombes RC, Ellin CL. 1990. Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. Eur J Cancer 26:824\u2013827.","journal-title":"Eur J Cancer"},{"key":"13_CR140","first-page":"107","volume":"1","author":"HT Mouridsen","year":"1980","unstructured":"Mouridsen HT, Salimtschik M, Dombernowsky P, Gelshoj K, Palshof T, Daehnfeldt JL, Rose C. 1980. Therapeutic effect of tamoxifen versus combined tamoxifen and dicthylstilboestrol in advanced breast cancer in postmenopausal women. Eur J Cancer Suppl 1: 107\u2013110.","journal-title":"Eur J Cancer Suppl"},{"key":"13_CR141","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.1988.6.5.825","volume":"6","author":"JN Ingle","year":"1988","unstructured":"Ingle JN, Twito DI, Schaid DJ, et al. 1988. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. J Clin Oncol 6:825\u2013831.","journal-title":"J Clin Oncol"},{"key":"13_CR142","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1200\/JCO.1986.4.6.958","volume":"4","author":"JN Ingle","year":"1986","unstructured":"Ingle JN, Green SJ, Ahmann DL, Long HJ, Edmonson JH, Rubin J, Chang MN, Creagan ET. 1986. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 4:958\u2013964.","journal-title":"J Clin Oncol"},{"key":"13_CR143","first-page":"5387","volume":"50","author":"WR Bezwoda","year":"1990","unstructured":"Bezwoda WR, Meyer K. 1990. Effect of alpha-interferon, 17 beta-estradiol, and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF 7 cells. Cancer Res 50:5387\u20135391.","journal-title":"Cancer Res"},{"key":"13_CR144","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/bjc.1993.339","volume":"68","author":"L Seymour","year":"1993","unstructured":"Seymour L, Bezwoda WR. 1993. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators. Br J Cancer 68:352\u2013356.","journal-title":"Br J Cancer"},{"key":"13_CR145","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.1993.11.3.474","volume":"11","author":"MA Cobleigh","year":"1993","unstructured":"Cobleigh MA, Dowlatshahi K, Deutsch TA, et al. 1993. Phase I\/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol 11:474\u2013477.","journal-title":"J Clin Oncol"},{"key":"13_CR146","first-page":"5711","volume":"54","author":"T Vink-van Wijngaarden","year":"1994","unstructured":"Vink-van Wijngaarden T, Pols HA, Buurman CJ, van den Bernd GJ, Dorssers LC, Birkenhager JC, van Leeuwen JP. 1994. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res 54:5711\u20135717.","journal-title":"Cancer Res"},{"key":"13_CR147","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0304-3835(95)03924-L","volume":"96","author":"E Candi","year":"1995","unstructured":"Candi E, Melino G, De Laurenzi V, Piacentini M, Guerrieri P, Spinedi A, Knight RA. 1995. Tamoxifen and somatostatin affect tumours by inducing apoptosis. Cancer Lett 96:141\u2013145.","journal-title":"Cancer Lett"},{"key":"13_CR148","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/bjc.1995.164","volume":"71","author":"P Lissoni","year":"1995","unstructured":"Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, Tancini G. 1995. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 71:854\u2013856.","journal-title":"Br J Cancer"},{"key":"13_CR149","first-page":"1","volume":"27","author":"SC Binder","year":"1977","unstructured":"Binder SC, Flynn WJ, Pass LM. 1977. Endocrine ablative therapy of metastatic breast cancer. CA 27:1\u20139.","journal-title":"CA"}],"container-title":["Cancer Treatment and Research","Biological and Hormonal Therapies of Cancer"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4615-6189-7_13.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T11:40:18Z","timestamp":1619869218000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4615-6189-7_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998]]},"ISBN":["9781461378372","9781461561897"],"references-count":149,"URL":"https:\/\/doi.org\/10.1007\/978-1-4615-6189-7_13","relation":{},"ISSN":["0927-3042"],"issn-type":[{"value":"0927-3042","type":"print"}],"subject":[],"published":{"date-parts":[[1998]]}}}